Claim Missing Document
Check
Articles

Found 16 Documents
Search

Acute Hemodynamic Index as a Predictor of In-Hospital Mortality in Mechanical Ventilated Acute Decompensated Heart Failure Patients Kurniawan, Dea Arie; Anjarwani, Setyasih; Rizal, Ardian; Satrijo, Budi; Yogibuana, Valerinna
Heart Science Journal Vol. 4 No. 1 (2023): Optimizing Outcome in Acute Cardiac Care
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2023.004.01.4

Abstract

Background: The likelihood of a poor clinical outcome is significantly increased in patients with acute decompensated heart failure. Mechanical ventilation was necessary for 23% of ADHF patients receiving treatment. The simple parameters of blood pressure and heart rate have good accuracy and repeatability. The development of the Acute Hemodynamic Index allowed for the calculation of pulse pressure and heart rate to be used as a basis for predicting intrahospital mortality.Methods: The medical records of patients who received care at CVCU RSSA were used in this retrospective, single-center study. ROC analysis and multivariate regression analysis were used to evaluate the prognostic performance of AHI. Statistical significance was determined by the P value of 0.05 or lower.Results: 252 patients with heart failure and low ejection fraction had their data analyzed. Hospital mortality is 82 percent. The cut-off was 4.19 mmHg/bpm, which was the AHI value. 68.8% of patients with fatal illnesses had low AHIs ( 4.19 mmHgbpm). AHI > 4.19 mmHgbpm patients have a 9-fold increased risk of dying in the hospital than patients with low AHI. AUC: 0.825 [0.743-0.907]; sensitivity: 0.814; specificity: 0.689; AUC: 0.825 [0.743-0.907; p = 0.000]; demonstrate the high predictive power of AHI.Conclusion: AHI has a strong degree of association with the likelihood of dying in the hospital from acute decompensated heart failure.
The role of green tea and green coffee extract, empagliflozin and metformin treatment on FGF23 mRNA expression in calcified aorta tissue in metabolic syndrome model Sprague-Dawley rat Kurniawan, Ary; Mohammad Saifur Rohman; Yogibuana, Valerinna
Heart Science Journal Vol. 7 No. 1 (2026): Accelerating Clinical Breakthroughs: The Journey from Molecular Discovery to Pa
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.01.11

Abstract

Background: Metabolic syndrome (MetS), encompassing dyslipidemia, glucose intolerance, hypertension, and central obesity, increases cardiovascular risk, including vascular calcification. Fibroblast growth factor 23 (FGF23), a bone-derived regulator of phosphate and vitamin D, is implicated in vascular calcification in kidney disease, but its role in MetS-related calcification is unclear. Objective: To determine if MetS promotes vascular calcification and alters aortic FGF23 mRNA expression in rats, and to assess effects of green tea/coffee extract, metformin, and empagliflozin on FGF23 mRNA modulation. Methods: Twenty-five Sprague-Dawley rats were divided into five groups: negative control, MetS (induced via high-fat/high-sucrose diet and streptozotocin), and three treatment groups (green tea/coffee extract, metformin 500mg/kg, empagliflozin 30mg/kg). Aortic calcification (hematoxylin-eosin staining) and FGF23 mRNA expression (qRT-PCR) were analyzed after 9 weeks. ANOVA with LSD post-hoc tests was used. Results: This study found MetS induction promoted vascular calcification. FGF23 mRNA expression increased in the MetS group compared to controls, though not statistically significant. All treatments reduced FGF23 mRNA levels modestly, but effects lacked statistical significance (p = 0.851–0.989), likely due to complex, tissue specific regulation of FGF23. Conclusion: Metabolic disturbances in MetS may prime vascular tissues for calcification without significantly altering local FGF23 mRNA expression. Interventions targeting oxidative stress, inflammation, or glucose metabolism could modulate FGF23-related pathways, warranting further investigation into the underlying signaling mechanisms.
A review of RUNX2 genetic interactions and their role in cardiovascular disease Christine, Anastasia; Rohman, Mohammad Saifur; Yogibuana, Valerinna
Heart Science Journal Vol. 7 No. 2 (2026): The Evolving Landscape of Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.02.5

Abstract

Cardiovascular diseases (CVD) remain the leading cause of global mortality, with underlying factors such as genetics, environment, and lifestyle interacting in complex and multiple ways. Runt-related transcription factor 2 (RUNX2), traditionally associated with osteogenesis, has gained recognition for its critical role in cardiovascular health. RUNX2 contributes to vascular calcification (VC), endothelial dysfunction, and myocardial fibrosis, thereby accelerating CVD progression. Its expression is influenced by multiple upstream regulators relevant to vascular pathology, such as BMP2/SMAD, Wnt/β-catenin, and ERK signaling, along with epigenetic mechanisms and gene-environment interactions such as oxidative stress, hyperglycemia, and dyslipidemia. Genetic variants in RUNX2 and environmental variables including diet and physical inactivity, amplify its activation, worsening VC and cardiovascular risk. RUNX2 reduces endothelial nitric oxide bioavailability, enhances vascular inflammation, and activates profibrotic signaling in cardiac tissue, promoting vascular dysfunction and myocardial remodeling. Circulating RUNX2 levels and genetic variations exhibit potential as diagnostic and predictive indicators for cardiovascular disease. Severalpharmaceutical agents including metformin, empagliflozin, and statins,   as well as natural substances such green tea polyphenols and green coffee extract, have demonstrated partial modulatory effects on RUNX2 activity. Moreover, genome-editing tools such as CRISPR-Cas9 present future opportunities for selective RUNX2 targeting. Comprehensive understanding of RUNX2 regulation and its interaction with genetic and environmental factors offers novel opportunities for personalized CVD prevention and treatment approaches through lifestyle modification, pharmacotherapy, and gene-based interventions in the future.
Prognostic implications of pulmonary hypertension in heart failure preserved and reduced ejection fraction Rosyidi, Muhammad Azhar; Yogibuana, Valerinna
Heart Science Journal Vol. 7 No. 2 (2026): The Evolving Landscape of Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.02.3

Abstract

Pulmonary hypertension (PH) attributable to left heart disease (PH associated with left heart disease, PH-LHD) is the most common type of PH. PH-LHD is an important indicator of elevated morbidity and mortality in individuals with heart failure, both heart failure with preserved and reduced ejection fraction despite receive adequate therapy. Literature was sourced from major scientific databases and studies relevant to symptoms, examinations, management, and prognostic implications of PH-LHD. Pathophysiologically, PH-LHD is a gradual process that begins with increased left-heart pressure (postcapillary component), which triggers a series of biological changes in the pulmonary vasculature (precapillary component). This process ultimately places an excessive burden on the right ventricle, resulting in right ventricular dysfunction and failure, which are the main determinants of prognosis. Symptoms of PH-LHD are usually characterized by disproportionate dyspnea that is not consistent with left ventricular ejection fraction and other comorbidities. Echocardiography can noninvasively assess the probability of pulmonary hypertension in heart failure patients. A definitive diagnosis of PH-LHD requires confirmation through right heart catheterization. The most important prognostic factors are not only determined by the degree of hemodynamic severity, but also depend heavily on the degree of right ventricular dysfunction and the status of right ventricle–pulmonary artery coupling. Management of PH-LHD is through optimization of basic Guideline-Directed Medical Therapy (GDMT) to reduce mortality and morbidity.
Effects of metformin and empagliflozin on runt- related transcription factor-2 (RUNX2) mRNA expression in vascular calcification of metabolic syndrome rats Christine, Anastasia; Rohman, Mohammad Saifur; Yogibuana, Valerinna
Heart Science Journal Vol. 7 No. 4 (2026): Navigating High-Risk Cardiovascular Subsets: Premature Disease, Plaque Complexi
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.04.5

Abstract

Background: Vascular calcification (VC) is a severe vascular complication of metabolic syndrome (MetS), strongly correlated with increased cardiovascular morbidity and mortality. One of the most important regulator of osteoblastic differentiation, runt-related transcription factor-2 (RUNX2) has a crucial role in VC by promoting the transformation of vascular smooth muscle cells (VSMCs) toward an osteoblast-like phenotype.Objective: This study explored the effect of MetS on VC by raising RUNX2 mRNA expression and how metformin and empagliflozin affect RUNX2 mRNA expression in MetS-induced rats.Methods:  Twenty Sprague-Dawley male rats were randomly separated into four groups: negative control (NC), MetS, MetS treated with metformin 500 mg/kgBW/day, and MetS treated with empagliflozin 30 mg/kgBW/day. MetS was induced by a high-fat high-sucrose diet and low-dose streptozotocin injection. RUNX2 mRNA expression was measured using RT-PCR and aortic tissue was stained using hematoxylin-eosin.Result: MetS induction resulted in visible microcalcification within the aortic wall and significantly increased RUNX2 mRNA expression compared with the NC group (mean ± SD: 38 ± 15, p = 0.01), indicating enhanced VC. Metformin markedly reduced RUNX2 mRNA expression (mean ± SD: 73 ± 7, p = 0.03), whereas empagliflozin showed a non-significant decrease (mean ± SD: 76 ± 23, p = 0.87). Conclusion: MetS induction can stimulate VC accompanied by increased RUNX2 mRNA expression in rats aortic tissue. Metformin and empagliflozin mitigate these changes, with metformin showing a more pronounced effect. This strengthens the importance of controlling MetS to reduce the risk of VC.
Longitudinal changes in right ventricular-pulmonary arterial coupling after defect closure in adult congenital heart disease: The LET SHINE registry Rahmawati, Novi; Yogibuana, Valerinna; Anjarwani, Setyasih
Heart Science Journal Vol. 7 No. 4 (2026): Navigating High-Risk Cardiovascular Subsets: Premature Disease, Plaque Complexi
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.04.9

Abstract

Background: Right ventricular-pulmonary arterial (RV-PA) coupling reflects right ventricular adaptation to afterload and can be estimated non-invasively by echocardiography. Whether coupling recovery after defect closure in adult left-to-right shunt congenital heart disease (CHD) differs by lesion location, and whether baseline coupling predicts persistent pulmonary hypertension (PH), remains poorly defined in Southeast Asian populations.Objective: To evaluate longitudinal change in echocardiographic RV-PA coupling after defect closure, compare trajectories between pre-tricuspid (atrial septal defect) and post-tricuspid (ventricular septal defect and patent ductus arteriosus) lesions, and assess baseline coupling as a predictor of persistent PH at 12 months.Methods:  This retrospective cohort study included 93 adults with left-to-right shunt CHD from the LET SHINE Registry who underwent defect closure and echocardiography at baseline (T0), 3 months (T1), and 12 months (T2), right heart catheterization is performed before the defect was closed. Six RV-PA coupling ratios (TAPSE/sPAP, TAPSE/PVAcT, TAPSE/TRV max, FAC/sPAP, FAC/PVAcT, FAC/TRV max) were compared across time, between lesion groups (Linear Mixed Model), and by ROC analysis for persistent PH (echocardiographic sPAP ≥35 mmHg at T2).Result: All six ratios improved significantly from T0 to T1 (p<0.001) and remained stable to T2. Pre-tricuspid lesions had lower baseline coupling but greater, more sustained improvement (group×time interaction p<0.001 for all ratios). Persistent PH occurred in 23/93 patients (24.7%). Baseline TAPSE/sPAP and FAC/sPAP discriminated persistent PH (AUC 0.780 and 0.786) comparably to invasive mPAP and PVR (AUC 0.805 and 0.800). Conclusion: RV-PA coupling improves substantially within 3 months after defect closure (all ratios, p<0,001), reflecting an acute fall in RV loading once the shunt is closed rather than slow structural remodelling, but follows a lesion-specific trajectory (group×time interaction p≤0,012; greater 12-month gains in pre-tricuspid than post-tricuspid lesions, Cohen's d 0,53-0,77), consistent with the differing reversibility of volume-overload (ASD) versus combined volume-pressure overload (VSD/PDA) remodelling. Baseline coupling ratios offer non-invasive predictive value for persistent PH (TAPSE/sPAP and FAC/sPAP AUC 0,780 dan 0,786) comparable to invasive hemodynamics (mPAP and PVR AUC 0,805 dan 0,800), because these ratios capture RV function relative to its afterload rather than contractility alone.